Comparing cost-effectiveness analyses for the clinical oncology setting: The example of the Gynecologic Oncology Group 111 trial

被引:3
作者
Bennett, CL [1 ]
Stinson, TJ [1 ]
机构
[1] Northwestern Univ, Sch Med, Div Hematol Oncol, Lakeside VA Med Ctr, Chicago, IL 60611 USA
关键词
D O I
10.3109/07357900009031829
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For the practicing oncologist, balancing quality of care with cost containment has become an unavoidable challenge. The development of new technologies, increased patient awareness, growth of managed care, and aging of our population represent conflicting interests in this endeavor. Medical literature has recently been inundated with economic analyses in an effort to approach some of these difficult questions, but often times it is difficult to see how this research applies to any particular oncologist's practice. This article identifies many of the key issues raised in the critical evaluation of cost-effectiveness analyses as they relate to the practicing oncologist. We offer suggestions on the interpretation of these studies to the clinical setting, using the recently published Journal of Clinical Oncology articles on cost-effectiveness analyses of paclitaxel-cisplatin as first-line therapy for ovarian cancer as examples.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 30 条
[1]   Second-look operation for epithelial ovarian cancer: Laparoscopy or laparotomy? [J].
AbuRustum, NR ;
Barakat, RR ;
Siegel, PL ;
Venkatraman, E ;
Curtin, JP ;
Hoskins, WJ .
OBSTETRICS AND GYNECOLOGY, 1996, 88 (04) :549-553
[2]  
Bennett CL, 1997, EUR UROL, V32, P86
[3]   COSTS OF CARE AND OUTCOMES FOR HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION FOR LYMPHOID MALIGNANCIES - RESULTS FROM THE UNIVERSITY-OF-NEBRASKA 1987 THROUGH 1991 [J].
BENNETT, CL ;
ARMITAGE, JL ;
ARMITAGE, GO ;
VOSE, JM ;
BIERMAN, PJ ;
ARMITAGE, JO ;
ANDERSON, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) :969-973
[4]   COSTS OF TERMINAL CARE FOR PEOPLE WITH AIDS [J].
BENNETT, CL ;
LUBECK, DP ;
MCSHANE, DJ ;
MATHEWS, JK ;
LIPIL, WH .
AIDS PATIENT CARE, 1995, 9 (01) :7-9
[5]   Economic analyses of phase III cooperative cancer group clinical trials: Are they feasible? [J].
Bennett, CL ;
Golub, R ;
Waters, TM ;
Tallman, MS ;
Rowe, JM .
CANCER INVESTIGATION, 1997, 15 (03) :227-236
[6]  
Bennett CL, 1998, INT J GYNECOL CANCER, V8, P64
[7]   SOURCES OF THE GROWTH IN MEDICARE PHYSICIAN EXPENDITURES [J].
BERENSON, R ;
HOLAHAN, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (05) :687-691
[8]  
CLERI LB, 1995, CANCER, V76, P774, DOI 10.1002/1097-0142(19950901)76:5<774::AID-CNCR2820760510>3.0.CO
[9]  
2-5
[10]  
DeCoster CA, 1997, PUBLIC HEALTH REP, V112, P298